AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer’s disease
pharmaceutical-investing Denali Therapeutics Announces Reports Full Year 2017 Financial Results And Business Highlights
pharmaceutical-investing Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis
ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Potential for Improved Therapeutic Potency
